

# Mark R Thursz

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/6328194/mark-r-thursz-publications-by-year.pdf>

**Version:** 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

220  
papers

9,067  
citations

54  
h-index

88  
g-index

300  
ext. papers

11,507  
ext. citations

8.2  
avg, IF

6.21  
L-index

#	Paper	IF	Citations
220	Non-selective beta-blocker use in cirrhosis: the additional benefit in preventing secondary infections.. <i>Frontline Gastroenterology</i> , <b>2022</b> , 13, 86-88	2.6	1
219	Mortality risk prediction of high-sensitivity C-reactive protein in suspected acute coronary syndrome: A cohort study.. <i>PLoS Medicine</i> , <b>2022</b> , 19, e1003911	11.6	3
218	Therapeutic advances in alcohol-associated hepatitis.. <i>Journal of Hepatology</i> , <b>2022</b> , 76, 1279-1290	13.4	0
217	Progress towards elimination of mother-to-child transmission of hepatitis B virus infection in China: a modelling analysis. <i>Bulletin of the World Health Organization</i> , <b>2021</b> , 99, 10-18	8.2	1
216	Multi-Arm Trial of Inflammatory Signal Inhibitors (MATIS) for Hospitalised Patients with Mild or Moderate COVID-19 Pneumonia: A Structured Summary of a Study Protocol for a Randomised Controlled Trial. <i>Blood</i> , <b>2021</b> , 138, 4200-4200	2.2	
215	Non-Alcoholic Fatty Liver Disease and Vascular Disease. <i>Current Vascular Pharmacology</i> , <b>2021</b> , 19, 269-279	3.3	6
214	A genetic risk score and diabetes predict development of alcohol-related cirrhosis in drinkers. <i>Journal of Hepatology</i> , <b>2021</b> ,	13.4	4
213	Cost effectiveness of simplified HCV screening-and-treatment interventions for people who inject drugs in Dar-es-Salaam, Tanzania. <i>International Journal of Drug Policy</i> , <b>2021</b> , 99, 103458	5.5	1
212	The global burden of chronic hepatitis B virus infection: comparison of country-level prevalence estimates from four research groups. <i>International Journal of Epidemiology</i> , <b>2021</b> , 50, 560-569	7.8	7
211	Clinical Characteristics and Predictors of Outcomes of Hospitalized Patients With Coronavirus Disease 2019 in a Multiethnic London National Health Service Trust: A Retrospective Cohort Study. <i>Clinical Infectious Diseases</i> , <b>2021</b> , 73, e4047-e4057	11.6	52
210	Clinical utility of quantifying hepatitis B surface antigen in African patients with chronic hepatitis B. <i>Journal of Viral Hepatitis</i> , <b>2021</b> , 28, 1003-1010	3.4	0
209	Rapid, non-invasive measurement of gastric emptying rate using transcutaneous fluorescence spectroscopy. <i>Biomedical Optics Express</i> , <b>2021</b> , 12, 4249-4264	3.5	0
208	Binge-eating disorder is associated with an unfavorable body mass composition in patients with non-alcoholic fatty liver disease. <i>International Journal of Eating Disorders</i> , <b>2021</b> , 54, 2025-2030	6.3	1
207	Cuts to UK official development assistance budget jeopardise global viral hepatitis elimination goals. <i>The Lancet Gastroenterology and Hepatology</i> , <b>2021</b> , 6, 527-528	18.8	
206	Disease Prevention Not Decolonization: A Model for Fecal Microbiota Transplantation in Patients Colonized With Multidrug-resistant Organisms. <i>Clinical Infectious Diseases</i> , <b>2021</b> , 72, 1444-1447	11.6	18
205	NAFLD: Time to apply quantitation in liver biopsies as endpoints in clinical trials. <i>Journal of Hepatology</i> , <b>2021</b> , 74, 241-242	13.4	0
204	Transition to decompensation and acute-on-chronic liver failure: Role of predisposing factors and precipitating events. <i>Journal of Hepatology</i> , <b>2021</b> , 75 Suppl 1, S36-S48	13.4	3

203	A global investment framework for the elimination of hepatitis B. <i>Journal of Hepatology</i> , <b>2021</b> , 74, 535-549	13.4	12
202	Economic and epidemiological evaluation of interventions to reduce the burden of hepatitis C in Yunnan province, China. <i>PLoS ONE</i> , <b>2021</b> , 16, e0245288	3.7	2
201	Characteristics and outcomes of clinically diagnosed RT-PCR swab negative COVID-19: a retrospective cohort study. <i>Scientific Reports</i> , <b>2021</b> , 11, 2455	4.9	6
200	Serum transferrin as a biomarker of hepatocyte nuclear factor 4 alpha activity and hepatocyte function in liver diseases. <i>BMC Medicine</i> , <b>2021</b> , 19, 39	11.4	2
199	PD-1 blockade improves Kupffer cell bacterial clearance in acute liver injury. <i>Journal of Clinical Investigation</i> , <b>2021</b> , 131,	15.9	10
198	Activation and transcriptional profile of monocytes and CD8 T cells are altered in checkpoint inhibitor-related hepatitis. <i>Journal of Hepatology</i> , <b>2021</b> , 75, 177-189	13.4	7
197	Fecal Microbiota Transplant Mitigates Adverse Outcomes Seen in Patients Colonized With Multidrug-Resistant Organisms Undergoing Allogeneic Hematopoietic Cell Transplantation. <i>Frontiers in Cellular and Infection Microbiology</i> , <b>2021</b> , 11, 684659	5.9	3
196	Liver function tests and metabolic-associated fatty liver disease: Changes in upper normal limits, does it really matter?. <i>World Journal of Hepatology</i> , <b>2021</b> , 13, 2104-2112	3.4	1
195	The diagnostic and prognostic significance of liver histology in alcoholic hepatitis. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2021</b> , 53, 426-431	6.1	6
194	Hepatitis B Core-related Antigen: An Alternative to Hepatitis B Virus DNA to Assess Treatment Eligibility in Africa. <i>Clinical Infectious Diseases</i> , <b>2020</b> , 70, 1442-1452	11.6	15
193	In Severe Alcoholic Hepatitis, Serum Keratin-18 Fragments Are Diagnostic, Prognostic, and Theragnostic Biomarkers. <i>American Journal of Gastroenterology</i> , <b>2020</b> , 115, 1857-1868	0.7	15
192	Immune-based therapies for hepatocellular carcinoma. <i>Oncogene</i> , <b>2020</b> , 39, 3620-3637	9.2	68
191	Prognostic significance of troponin level in 3121 patients presenting with atrial fibrillation (The NIHHR Health Informatics Collaborative TROP-AF study). <i>Journal of the American Heart Association</i> , <b>2020</b> , 9, e013684	6	8
190	Serum Transferrin Is an Independent Predictor of Mortality in Severe Alcoholic Hepatitis. <i>American Journal of Gastroenterology</i> , <b>2020</b> , 115, 398-405	0.7	16
189	Trace element deficiency is highly prevalent and associated with infection and mortality in patients with alcoholic hepatitis. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2020</b> , 52, 537-544	6.1	7
188	Validity of the UK early access to medicines scheme criteria for Remdesivir use in patients with COVID-19 disease. <i>Journal of Infection</i> , <b>2020</b> , 81, 647-679	18.9	1
187	Response to Diao et al. <i>American Journal of Gastroenterology</i> , <b>2020</b> , 115, 958	0.7	
186	Response to Sainath et al. <i>American Journal of Gastroenterology</i> , <b>2020</b> , 115, 1136-1137	0.7	

185	Androgenic anabolic steroid-induced liver injury: two case reports assessed for causality by the updated Roussel Uclaf Causality Assessment Method (RUCAM) score and a comprehensive review of the literature. <i>BMJ Open Gastroenterology</i> , <b>2020</b> , 7,	3.9	3
184	Genome-wide meta-analysis of problematic alcohol use in 435,563 individuals yields insights into biology and relationships with other traits. <i>Nature Neuroscience</i> , <b>2020</b> , 23, 809-818	25.5	69
183	High-Throughput, Machine Learning-Based Quantification of Steatosis, Inflammation, Ballooning, and Fibrosis in Biopsies From Patients With Nonalcoholic Fatty Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , <b>2020</b> , 18, 2081-2090.e9	6.9	35
182	In-field evaluation of Xpert <sup>®</sup> HCV viral load Fingerstick assay in people who inject drugs in Tanzania. <i>Liver International</i> , <b>2020</b> , 40, 514-521	7.9	16
181	Time matters: Point of care screening and streamlined linkage to care dramatically improves hepatitis C treatment uptake in prisoners in England. <i>International Journal of Drug Policy</i> , <b>2020</b> , 75, 102608	5.5	15
180	Recent advances in alcohol-related liver disease (ALD): summary of a Gut round table meeting. <i>Gut</i> , <b>2020</b> , 69, 764-780	19.2	39
179	In-hospital mortality is associated with inflammatory response in NAFLD patients admitted for COVID-19. <i>PLoS ONE</i> , <b>2020</b> , 15, e0240400	3.7	24
178	Leucocyte ratios are biomarkers of mortality in patients with acute decompensation of cirrhosis and acute-on-chronic liver failure. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2020</b> , 52, 855-865	6.1	12
177	Intestinal permeability and bacterial translocation in patients with liver disease, focusing on alcoholic aetiology: methods of assessment and therapeutic intervention. <i>Therapeutic Advances in Gastroenterology</i> , <b>2020</b> , 13, 1756284820942616	4.7	7
176	Effect of COVID-19 lockdown on alcohol consumption in patients with pre-existing alcohol use disorder. <i>The Lancet Gastroenterology and Hepatology</i> , <b>2020</b> , 5, 886-887	18.8	83
175	Hepatitis B virus preS2 <sup>Δ</sup> 8-55 variants: A newly identified risk factor for hepatocellular carcinoma. <i>JHEP Reports</i> , <b>2020</b> , 2, 100144	10.3	8
174	Cost-effectiveness of strategies to improve HCV screening, linkage-to-care and treatment in remand prison settings in England. <i>Liver International</i> , <b>2020</b> , 40, 2950-2960	7.9	3
173	Global hepatitis C elimination: an investment framework. <i>The Lancet Gastroenterology and Hepatology</i> , <b>2020</b> , 5, 927-939	18.8	16
172	Transcutaneous fluorescence spectroscopy as a tool for non-invasive monitoring of gut function: first clinical experiences. <i>Scientific Reports</i> , <b>2020</b> , 10, 16169	4.9	5
171	Invasive versus non-invasive management of older patients with non-ST elevation myocardial infarction (SENIOR-NSTEMI): a cohort study based on routine clinical data. <i>Lancet, The</i> , <b>2020</b> , 396, 623-634	10	27
170	Genetic variation in HSD17B3 reduces the risk for developing severe alcoholic hepatitis. <i>Journal of Hepatology</i> , <b>2020</b> , 73, S61-S62	13.4	2
169	Understanding the mechanisms of efficacy of fecal microbiota transplant in treating recurrent infection and beyond: the contribution of gut microbial-derived metabolites. <i>Gut Microbes</i> , <b>2020</b> , 12, 1810531	8.8	12
168	Early Health Technology Assessment during Nonalcoholic Steatohepatitis Drug Development: A Two-Round, Cross-Country, Multicriteria Decision Analysis. <i>Medical Decision Making</i> , <b>2020</b> , 40, 830-845	2.5	4

167	Histopathological findings and viral tropism in UK patients with severe fatal COVID-19: a post-mortem study. <i>Lancet Microbe, The</i> , <b>2020</b> , 1, e245-e253	22.2	270
166	Assessment and Management of Infection in Alcoholic Hepatitis. <i>Seminars in Liver Disease</i> , <b>2020</b> , 40, 11-19	3	3
165	Innovative strategies for the elimination of viral hepatitis at a national level: A country case series. <i>Liver International</i> , <b>2019</b> , 39, 1818-1836	7.9	25
164	Scaling up prevention and treatment towards the elimination of hepatitis C: a global mathematical model. <i>Lancet, The</i> , <b>2019</b> , 393, 1319-1329	40	130
163	High prevalence and poor linkage to care of transfusion-transmitted infections among blood donors in Dar-es-Salaam, Tanzania. <i>Journal of Viral Hepatitis</i> , <b>2019</b> , 26, 750-756	3.4	6
162	Systematic review with meta-analysis: high mortality in patients with non-severe alcoholic hepatitis. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2019</b> , 50, 249-257	6.1	14
161	Identification of mutations in circulating cell-free tumour DNA as a biomarker in hepatocellular carcinoma. <i>European Journal of Cancer</i> , <b>2019</b> , 116, 56-66	7.5	25
160	Derivation and validation of a cardiovascular risk score for prediction of major acute cardiovascular events in non-alcoholic fatty liver disease; the importance of an elevated mean platelet volume. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2019</b> , 49, 1077-1085	6.1	21
159	Clinical utility of TREAT-B score in African and non-African HBV-infected patients living in Europe. <i>Journal of Hepatology</i> , <b>2019</b> , 70, 1295-1297	13.4	6
158	Microbial bile salt hydrolases mediate the efficacy of faecal microbiota transplant in the treatment of recurrent infection. <i>Gut</i> , <b>2019</b> , 68, 1791-1800	19.2	100
157	ACG Clinical Guideline for Alcoholic Liver Disease: The MELD Threshold for Corticosteroid Treatment has Yet to be Established. <i>American Journal of Gastroenterology</i> , <b>2019</b> , 114, 175-176	0.7	5
156	The effects of dietary supplementation with inulin and inulin-propionate ester on hepatic steatosis in adults with non-alcoholic fatty liver disease. <i>Diabetes, Obesity and Metabolism</i> , <b>2019</b> , 21, 372-376	6.7	42
155	Strategies for Global Elimination of Chronic HBV Infection: 2019 Update. <i>Current Hepatology Reports</i> , <b>2019</b> , 18, 300-309	1	5
154	Defective HNF4alpha-dependent gene expression as a driver of hepatocellular failure in alcoholic hepatitis. <i>Nature Communications</i> , <b>2019</b> , 10, 3126	17.4	46
153	Baseline neutrophil-to-lymphocyte ratio predicts response to corticosteroids and is associated with infection and renal dysfunction in alcoholic hepatitis. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2019</b> , 50, 442-453	6.1	25
152	CD8T cells from patients with cirrhosis display a phenotype that may contribute to cirrhosis-associated immune dysfunction. <i>EBioMedicine</i> , <b>2019</b> , 49, 258-268	8.8	20
151	Letter: role of mean platelet volume levels in the prediction of major acute cardiovascular events in patients with non-alcoholic fatty liver disease-authorsReply. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2019</b> , 50, 1140-1141	6.1	
150	The future of therapy for alcoholic hepatitis - Beyond corticosteroids. <i>Journal of Hepatology</i> , <b>2019</b> , 70, 785-787	13.4	4

149	P: 81 Previously Identified Candidate Gene Associations in Hepatic Encephalopathy Do Not Replicate in the STOPAH Cohort. <i>American Journal of Gastroenterology</i> , <b>2019</b> , 114, S39-S39	0.7	
148	Monocyte-macrophage activation is associated with nonalcoholic fatty liver disease and liver fibrosis in HIV mono-infection independently of the gut microbiome and bacterial translocation. <i>Aids</i> , <b>2019</b> , 33, 805-814	3.5	11
147	Interleukin 28A.rs12980602 and interleukin 28B.rs8103142 genotypes could be protective against HCV infection among Egyptians. <i>Immunologic Research</i> , <b>2019</b> , 67, 123-133	4.3	4
146	Accelerating the elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission. <i>The Lancet Gastroenterology and Hepatology</i> , <b>2019</b> , 4, 135-184	18.8	216
145	Alcohol-related liver disease: Areas of consensus, unmet needs and opportunities for further study. <i>Journal of Hepatology</i> , <b>2019</b> , 70, 521-530	13.4	45
144	Endpoints and patient stratification in clinical trials for alcoholic hepatitis. <i>Journal of Hepatology</i> , <b>2019</b> , 70, 314-318	13.4	5
143	Reply to: "The long-term prognosis of alcoholic hepatitis is poor and independent of disease severity for patients surviving an acute episode". <i>Journal of Hepatology</i> , <b>2018</b> , 68, 1332	13.4	
142	EASL Clinical Practice Guidelines: Management of alcohol-related liver disease. <i>Journal of Hepatology</i> , <b>2018</b> , 69, 154-181	13.4	298
141	People who survive an episode of severe alcoholic hepatitis should be advised to maintain total abstinence from alcohol. <i>Hepatology</i> , <b>2018</b> , 67, 2479-2480	11.2	2
140	Functional microbiomics: Evaluation of gut microbiota-bile acid metabolism interactions in health and disease. <i>Methods</i> , <b>2018</b> , 149, 49-58	4.6	44
139	Rifaximin in non-alcoholic steatohepatitis: An open-label pilot study. <i>Hepatology Research</i> , <b>2018</b> , 48, 69-77	7.1	22
138	MerTK expressing hepatic macrophages promote the resolution of inflammation in acute liver failure. <i>Gut</i> , <b>2018</b> , 67, 333-347	19.2	88
137	CD14 CD15 HLA-DR myeloid-derived suppressor cells impair antimicrobial responses in patients with acute-on-chronic liver failure. <i>Gut</i> , <b>2018</b> , 67, 1155-1167	19.2	57
136	The hepatitis C cascade of care in people who inject drugs in Dar es Salaam, Tanzania. <i>Journal of Viral Hepatitis</i> , <b>2018</b> , 25, 1438-1445	3.4	21
135	The Micro-Elimination Approach to Eliminating Hepatitis C: Strategic and Operational Considerations. <i>Seminars in Liver Disease</i> , <b>2018</b> , 38, 181-192	7.3	113
134	Thrombin and factor Xa link the coagulation system with liver fibrosis. <i>BMC Gastroenterology</i> , <b>2018</b> , 18, 60	3	24
133	Prevalent acute-on-chronic liver failure and response to corticosteroids in alcoholic hepatitis. <i>Journal of Hepatology</i> , <b>2018</b> , 69, 1200-1201	13.4	13
132	Reply to: "The PNPLA3 SNP rs738409:G allele is associated with increased liver disease-associated mortality but reduced overall mortality in a population-based cohort". <i>Journal of Hepatology</i> , <b>2018</b> , 68, 860-862	13.4	2



131	Application of prognostic scores in the STOPAH trial: Discriminant function is no longer the optimal scoring system in alcoholic hepatitis. <i>Journal of Hepatology</i> , <b>2018</b> , 68, 511-518	13.4	41
130	Inhibiting Growth of <i>Clostridioides difficile</i> by Restoring Valerate, Produced by the Intestinal Microbiota. <i>Gastroenterology</i> , <b>2018</b> , 155, 1495-1507.e15	13.3	70
129	Antibiotic-Associated Disruption of Microbiota Composition and Function in Cirrhosis Is Restored by Fecal Transplant. <i>Hepatology</i> , <b>2018</b> , 68, 1205	11.2	4
128	Corticosteroids Reduce Risk of Death Within 28 Days for Patients With Severe Alcoholic Hepatitis, Compared With Pentoxifylline or Placebo-a Meta-analysis of Individual Data From Controlled Trials. <i>Gastroenterology</i> , <b>2018</b> , 155, 458-468.e8	13.3	76
127	Development of a simple score based on HBeAg and ALT for selecting patients for HBV treatment in Africa. <i>Journal of Hepatology</i> , <b>2018</b> , 69, 776-784	13.4	32
126	Diagnostic accuracy of the gamma-glutamyl transpeptidase to platelet ratio (GPR) using transient elastography as a reference. <i>Gut</i> , <b>2017</b> , 66, 195-196	19.2	13
125	The clinical role of circulating free tumor DNA in gastrointestinal malignancy. <i>Translational Research</i> , <b>2017</b> , 183, 137-154	11	10
124	Community-based screening and treatment for chronic hepatitis B in sub-Saharan Africa - AuthorsO reply. <i>The Lancet Global Health</i> , <b>2017</b> , 5, e35	13.6	1
123	Anticoagulation in chronic liver disease. <i>Journal of Hepatology</i> , <b>2017</b> , 66, 1313-1326	13.4	36
122	Defective monocyte oxidative burst predicts infection in alcoholic hepatitis and is associated with reduced expression of NADPH oxidase. <i>Gut</i> , <b>2017</b> , 66, 519-529	19.2	37
121	Homozygosity for rs738409:G in PNPLA3 is associated with increased mortality following an episode of severe alcoholic hepatitis. <i>Journal of Hepatology</i> , <b>2017</b> , 67, 120-127	13.4	36
120	Prevalence and risk factors of nonalcoholic fatty liver disease in HIV-monoinfection. <i>Aids</i> , <b>2017</b> , 31, 1621-1632	13.3	91
119	Understanding the Mechanisms of Efficacy of Fecal Microbiota Transplantation in the Treatment of <i>Clostridium Difficile</i> Infection: The Potential Role of Bilemetabolising Enzymes. <i>Gastroenterology</i> , <b>2017</b> , 152, S47	13.3	2
118	Increased Expression of Cytotoxic T-Lymphocyte-Associated Protein 4 by T Cells, Induced by B7 in Sera, Reduces Adaptive Immunity in Patients With Acute Liver Failure. <i>Gastroenterology</i> , <b>2017</b> , 153, 263-276.e8 <sup>25</sup>	13.2	25
117	In Patients With Severe Alcoholic Hepatitis, Prednisolone Increases Susceptibility to Infection and Infection-Related Mortality, and Is Associated With High Circulating Levels of Bacterial DNA. <i>Gastroenterology</i> , <b>2017</b> , 152, 1068-1077.e4	13.3	92
116	Clinical utility of HCV core antigen detection and quantification using serum samples and dried blood spots in people who inject drugs in Dar-es-Salaam, Tanzania. <i>Journal of the International AIDS Society</i> , <b>2017</b> , 20, 21856	5.4	32
115	Economic evaluations of HBV testing and treatment strategies and applicability to low and middle-income countries. <i>BMC Infectious Diseases</i> , <b>2017</b> , 17, 692	4	13
114	Absolute quantitation of disease protein biomarkers in a single LC-MS acquisition using apolipoprotein F as an example. <i>Scientific Reports</i> , <b>2017</b> , 7, 12072	4.9	4

113	Fecal microbiota transplant from a rational stool donor improves hepatic encephalopathy: A randomized clinical trial. <i>Hepatology</i> , <b>2017</b> , 66, 1354-1355	11.2	13
112	A clinician® guide to the cost and health benefits of hepatitis C cure assessed from the individual patient perspective. <i>European Journal of Gastroenterology and Hepatology</i> , <b>2017</b> , 29, 208-214	2.2	4
111	Battlefield against hepatitis B infection and HCC in Africa. <i>Journal of Hepatology</i> , <b>2017</b> , 66, 645-654	13.4	58
110	The cost impact of outreach testing and treatment for hepatitis C in an urban Drug Treatment Unit. <i>Liver International</i> , <b>2017</b> , 37, 345-353	7.9	20
109	Hepatitis B testing and treatment in HIV patients in The Gambia-Compliance with international guidelines and clinical outcomes. <i>PLoS ONE</i> , <b>2017</b> , 12, e0179025	3.7	12
108	Natural history of chronic HBV infection in West Africa: a longitudinal population-based study from The Gambia. <i>Gut</i> , <b>2016</b> , 65, 2007-2016	19.2	83
107	The gamma-glutamyl transpeptidase to platelet ratio (GPR) predicts significant liver fibrosis and cirrhosis in patients with chronic HBV infection in West Africa. <i>Gut</i> , <b>2016</b> , 65, 1369-76	19.2	198
106	Global metabolic changes induced by plant-derived pyrrolizidine alkaloids following a human poisoning outbreak and in a mouse model. <i>Toxicology Research</i> , <b>2016</b> , 5, 1594-1603	2.6	
105	Requirements for global elimination of hepatitis B: a modelling study. <i>Lancet Infectious Diseases</i> , <b>2016</b> , 16, 1399-1408	25.5	186
104	Mother-to-child transmission of hepatitis B in sub-Saharan Africa. <i>Lancet Infectious Diseases</i> , <b>2016</b> , 16, 19-20	25.5	15
103	Treatment of Severe Alcoholic Hepatitis. <i>Gastroenterology</i> , <b>2016</b> , 150, 1823-34	13.3	33
102	Functional imaging of hepatocellular carcinoma. <i>Hepatic Oncology</i> , <b>2016</b> , 3, 137-153	4	0
101	Optimized Sample Handling Strategy for Metabolic Profiling of Human Feces. <i>Analytical Chemistry</i> , <b>2016</b> , 88, 4661-8	7.8	97
100	Cost-effectiveness of community-based screening and treatment for chronic hepatitis B in The Gambia: an economic modelling analysis. <i>The Lancet Global Health</i> , <b>2016</b> , 4, e568-78	13.6	64
99	Acceptability and feasibility of a screen-and-treat programme for hepatitis B virus infection in The Gambia: the Prevention of Liver Fibrosis and Cancer in Africa (PROLIFICA) study. <i>The Lancet Global Health</i> , <b>2016</b> , 4, e559-67	13.6	95
98	Patients with acute-on-chronic liver failure have increased numbers of regulatory immune cells expressing the receptor tyrosine kinase MERTK. <i>Gastroenterology</i> , <b>2015</b> , 148, 603-615.e14	13.3	148
97	Early diagnosis and treatment: the goal of hepatitis C screening. <i>BMJ</i> , <b>2015</b> , 350, h635	5.9	1
96	Next-generation sequencing sheds light on the natural history of hepatitis C infection in patients who fail treatment. <i>Hepatology</i> , <b>2015</b> , 61, 88-97	11.2	32



95	Comparative Effectiveness of Pharmacological Interventions for Severe Alcoholic Hepatitis: A Systematic Review and Network Meta-analysis. <i>Gastroenterology</i> , <b>2015</b> , 149, 958-70.e12	13.3	95
94	Prednisolone or Pentoxifylline for Alcoholic Hepatitis. <i>New England Journal of Medicine</i> , <b>2015</b> , 373, 282-392	39.2	35
93	Prednisolone or pentoxifylline for alcoholic hepatitis. <i>New England Journal of Medicine</i> , <b>2015</b> , 372, 1619-382	38.2	412
92	Influence of IFNL3.rs12979860 and IFNL4.ss469415590 polymorphism on clearance of hepatitis C virus infection among Egyptians. <i>Hepatology International</i> , <b>2015</b> , 9, 251-7	8.8	13
91	The prevalence and burden of symptoms in patients with chronic liver diseases in The Gambia, West Africa. <i>Palliative Medicine</i> , <b>2015</b> , 29, 184-5	5.5	7
90	Acute alcoholic hepatitis and cellular Th1 immune responses to alcohol dehydrogenase. <i>Lancet, The</i> , <b>2015</b> , 385 Suppl 1, S22	40	5
89	Is antenatal screening for hepatitis C virus cost-effective? A decade's experience at a London centre. <i>Journal of Hepatology</i> , <b>2015</b> , 63, 797-804	13.4	33
88	Mother-to-child transmission of hepatitis B virus in sub-Saharan Africa: time to act. <i>The Lancet Global Health</i> , <b>2015</b> , 3, e358-9	13.6	30
87	The role of intestinal microbiota in murine models of acetaminophen-induced hepatotoxicity. <i>Liver International</i> , <b>2015</b> , 35, 764-73	7.9	36
86	Birth order and risk of hepatocellular carcinoma in chronic carriers of hepatitis B virus: a case-control study in The Gambia. <i>Liver International</i> , <b>2015</b> , 35, 2318-26	7.9	22
85	Screening and treatment of hepatitis B virus to prevent liver cancer in Africa. <i>Hepatic Oncology</i> , <b>2015</b> , 2, 105-109	4	
84	Treatment of alcoholic hepatitis <b>2015</b> , 203-214		
83	Design, method and application of stopping rules in a phase III 2x2 factorial randomised controlled trial. <i>Trials</i> , <b>2015</b> , 16,	2.8	78
82	Reply: To PMID 24797101. <i>Hepatology</i> , <b>2015</b> , 61, 1438	11.2	
81	Blockade of PD1 and TIM3 restores innate and adaptive immunity in patients with acute alcoholic hepatitis. <i>Gastroenterology</i> , <b>2015</b> , 148, 590-602.e10	13.3	124
80	Validation of rapid point-of-care (POC) tests for detection of hepatitis B surface antigen in field and laboratory settings in the Gambia, Western Africa. <i>Journal of Clinical Microbiology</i> , <b>2015</b> , 53, 1156-63	9.7	62
79	The clinical effectiveness and cost-effectiveness of STeroids Or Pentoxifylline for Alcoholic Hepatitis (STOPAH): a 2x2 factorial randomised controlled trial. <i>Health Technology Assessment</i> , <b>2015</b> , 19, 1-104	4.4	24
78	Basis of HBV persistence and new treatment options. <i>Hepatology International</i> , <b>2014</b> , 8 Suppl 2, 486-91	8.8	4

77	Hirmi Valley liver disease: a disease associated with exposure to pyrrolizidine alkaloids and DDT. <i>Journal of Hepatology</i> , <b>2014</b> , 60, 96-102	13.4	35
76	Secretory leukocyte protease inhibitor: a pivotal mediator of anti-inflammatory responses in acetaminophen-induced acute liver failure. <i>Hepatology</i> , <b>2014</b> , 59, 1564-76	11.2	62
75	Discovery and validation of urinary metabotypes for the diagnosis of hepatocellular carcinoma in West Africans. <i>Hepatology</i> , <b>2014</b> , 60, 1291-301	11.2	49
74	HCV transmission in industrialized countries and resource-constrained areas. <i>Nature Reviews Gastroenterology and Hepatology</i> , <b>2014</b> , 11, 28-35	24.2	78
73	Modulation of monocyte/macrophage function: a therapeutic strategy in the treatment of acute liver failure. <i>Journal of Hepatology</i> , <b>2014</b> , 61, 439-45	13.4	92
72	Population-based interventions to reduce the public health burden related with hepatitis B virus infection in the gambia, west Africa. <i>Tropical Medicine and Health</i> , <b>2014</b> , 42, 59-64	3.4	9
71	Detection of allele specific differences in IFNL3 (IL28B) mRNA expression. <i>BMC Medical Genetics</i> , <b>2014</b> , 15, 104	2.1	4
70	Hepatitis C, a global issue: access to care and new therapeutic and preventive approaches in resource-constrained areas. <i>Seminars in Liver Disease</i> , <b>2014</b> , 34, 89-97	7.3	26
69	Forgotten, not neglected: viral hepatitis in resource-limited settings, recall for action. <i>Liver International</i> , <b>2014</b> , 34, 12-5	7.9	12
68	Overview of hepatitis B prevalence, prevention, and management in the Pacific Islands and Territories. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2014</b> , 29, 1854-66	4	12
67	Steroids or pentoxifylline for alcoholic hepatitis (STOPAH): study protocol for a randomised controlled trial. <i>Trials</i> , <b>2013</b> , 14, 262	2.8	45
66	Natural NS3 resistance polymorphisms occur frequently prior to treatment in HIV-positive patients with acute hepatitis C. <i>Aids</i> , <b>2013</b> , 27, 2485-8	3.5	14
65	Viral hepatitis in resource-limited countries and access to antiviral therapies: current and future challenges. <i>Future Virology</i> , <b>2013</b> , 8, 371-380	2.4	86
64	Character and temporal evolution of apoptosis in acetaminophen-induced acute liver failure*. <i>Critical Care Medicine</i> , <b>2013</b> , 41, 2543-50	1.4	31
63	The diversity and management of chronic hepatitis B virus infections in the United Kingdom: a wake-up call. <i>Clinical Infectious Diseases</i> , <b>2013</b> , 56, 951-60	11.6	30
62	Piloting a multidisciplinary clinic for the management of non-alcoholic fatty liver disease: initial 5-year experience. <i>Frontline Gastroenterology</i> , <b>2013</b> , 4, 263-269	2.6	15
61	Genetic variation in the interleukin-28B gene is associated with spontaneous clearance and progression of hepatitis C virus in Moroccan patients. <i>PLoS ONE</i> , <b>2013</b> , 8, e54793	3.7	32
60	Mutations in Mll2, an H3K4 methyltransferase, result in insulin resistance and impaired glucose tolerance in mice. <i>PLoS ONE</i> , <b>2013</b> , 8, e61870	3.7	31

59	Lipid profiling of pre-treatment liver biopsy tissue predicts sustained virological response in patients with chronic hepatitis C. <i>Hepatology Research</i> , <b>2012</b> , 42, 714-20	5.1	2
58	Proteomic analysis of extracellular matrix from the hepatic stellate cell line LX-2 identifies CYR61 and Wnt-5a as novel constituents of fibrotic liver. <i>Journal of Proteome Research</i> , <b>2012</b> , 11, 4052-64	5.6	58
57	Source and characterization of hepatic macrophages in acetaminophen-induced acute liver failure in humans. <i>Hepatology</i> , <b>2012</b> , 56, 735-46	11.2	192
56	Quantifying hepatic steatosis - more than meets the eye. <i>Histopathology</i> , <b>2012</b> , 60, 971-81	7.3	54
55	In the shadow of HIV/AIDS: forgotten diseases in sub-Saharan Africa: global health issues and funding agency responsibilities. <i>Journal of Public Health Policy</i> , <b>2012</b> , 33, 430-8	2.9	15
54	A polymorphism in IL28B distinguishes exposed, uninfected individuals from spontaneous resolvers of HCV infection. <i>Gastroenterology</i> , <b>2011</b> , 141, 320-5, 325.e1-2	13.3	62
53	The role of hypercoagulability in liver fibrogenesis. <i>Clinics and Research in Hepatology and Gastroenterology</i> , <b>2011</b> , 35, 526-33	2.4	64
52	Blunted increase in serum hepcidin as response to oral iron in HFE-hemochromatosis. <i>European Journal of Gastroenterology and Hepatology</i> , <b>2011</b> , 23, 721-4	2.2	4
51	Treatment of chronic hepatitis B virus infection in resource-constrained settings: expert panel consensus. <i>Liver International</i> , <b>2011</b> , 31, 755-61	7.9	53
50	Multi-excitation fluorescence spectroscopy for analysis of non-alcoholic fatty liver disease. <i>Lasers in Surgery and Medicine</i> , <b>2011</b> , 43, 392-400	3.6	10
49	Understanding the host genetics of chronic hepatitis B and C. <i>Seminars in Liver Disease</i> , <b>2011</b> , 31, 115-27	7.3	70
48	Can antiviral therapy of chronic hepatitis B prevent the development of hepatocellular carcinoma?. <i>Gut</i> , <b>2011</b> , 60, 1025-6	19.2	6
47	Host surfactant proteins in microbial recognition <b>2010</b> , 697-713		
46	Helicobacter pylori stimulates dendritic cells to induce interleukin-17 expression from CD4+ T lymphocytes. <i>Infection and Immunity</i> , <b>2010</b> , 78, 845-53	3.7	74
45	Impact of pan-caspase inhibition in animal models of established steatosis and non-alcoholic steatohepatitis. <i>Journal of Hepatology</i> , <b>2010</b> , 53, 542-50	13.4	122
44	The role of different EASL-papers: Clinical practice guidelines vs. position papers vs. conference summaries. <i>Journal of Hepatology</i> , <b>2010</b> , 53, 221	13.4	4
43	Presence of hepcidin-25 in biological fluids: bile, ascitic and pleural fluids. <i>World Journal of Gastroenterology</i> , <b>2010</b> , 16, 2129-33	5.6	11
42	Hepcidin levels in hereditary hyperferritinemia: Insights into the iron-sensing mechanism in hepatocytes. <i>World Journal of Gastroenterology</i> , <b>2010</b> , 16, 3541-5	5.6	3

41	Granulocyte colony-stimulating factor as a novel adjunct to improve hepatitis B vaccination. <i>World Journal of Hepatology</i> , <b>2010</b> , 2, 136-8	3.4	2
40	Phenotyping murine models of non-alcoholic fatty liver disease through metabolic profiling of intact liver tissue. <i>Clinical Science</i> , <b>2009</b> , 116, 403-13	6.5	29
39	Parenchymal extinction: coagulation and hepatic fibrogenesis. <i>Clinics in Liver Disease</i> , <b>2009</b> , 13, 117-126	4.6	67
38	Effect of a thrombin receptor (protease-activated receptor 1, PAR-1) gene polymorphism in chronic hepatitis C liver fibrosis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2008</b> , 23, 1403-9	4	25
37	NICE Guidelines and a Treatment Algorithm for the Management of Chronic Hepatitis B: A Review of 12 Years Experience in West London. <i>Antiviral Therapy</i> , <b>2008</b> , 13, 1067-1076	1.6	4
36	TLR9 polymorphisms determine murine lymphocyte responses to Helicobacter: results from a genome-wide scan. <i>European Journal of Immunology</i> , <b>2007</b> , 37, 1548-61	6.1	14
35	Influence of IL-10RA and IL-22 polymorphisms on outcome of hepatitis C virus infection. <i>Liver International</i> , <b>2007</b> , 27, 1134-43	7.9	43
34	Helicobacter infection in the surfactant protein D-deficient mouse. <i>Helicobacter</i> , <b>2007</b> , 12, 112-23	4.9	10
33	Iron, haemochromatosis and thalassaemia as risk factors for fibrosis in hepatitis C virus infection. <i>Gut</i> , <b>2007</b> , 56, 613-4	19.2	15
32	Class II cytokine receptor gene cluster is a major locus for hepatitis B persistence. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2006</b> , 103, 9148-53	11.5	81
31	Chronic hepatitis B virus infection in the Asia-Pacific region and Africa: review of disease progression. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2005</b> , 20, 833-43	4	57
30	Role of surfactant protein D (SP-D) in innate immunity in the gastric mucosa: evidence of interaction with Helicobacter pylori lipopolysaccharide. <i>Journal of Endotoxin Research</i> , <b>2005</b> , 11, 357-62		15
29	Variations in Helicobacter pylori lipopolysaccharide to evade the innate immune component surfactant protein D. <i>Infection and Immunity</i> , <b>2005</b> , 73, 7677-86	3.7	52
28	Esophageal cancer staging with endoscopic MR imaging: pilot study. <i>Radiology</i> , <b>2004</b> , 230, 281-6	20.5	37
27	Autoregulatory role of interleukin-10 in hepatitis C patients treated with IFN-alpha. <i>Journal of Interferon and Cytokine Research</i> , <b>2004</b> , 24, 585-93	3.5	8
26	In vitro 1H-magnetic resonance spectroscopy of Barrett's esophageal mucosa using magic angle spinning techniques. <i>European Journal of Gastroenterology and Hepatology</i> , <b>2004</b> , 16, 1199-205	2.2	10
25	Genetic diversity in the major histocompatibility complex and the immune response to infectious diseases <b>2003</b> , 77-116		1
24	Interleukin-10 promoter polymorphisms and the outcome of hepatitis C virus infection. <i>Immunogenetics</i> , <b>2003</b> , 55, 362-9	3.2	139

23	Association of genetic variants of the chemokine receptor CCR5 and its ligands, RANTES and MCP-2, with outcome of HCV infection. <i>Hepatology</i> , <b>2003</b> , 38, 1468-76	11.2	89
22	Quantitative versus morphological assessment of liver fibrosis: semi-quantitative scores are more robust than digital image fibrosis area estimation. <i>Liver International</i> , <b>2003</b> , 23, 28-34	7.9	41
21	Expression of surfactant protein D in the human gastric mucosa and during <i>Helicobacter pylori</i> infection. <i>Infection and Immunity</i> , <b>2002</b> , 70, 1481-7	3.7	50
20	Factor V Leiden Polymorphism and the Rate of Fibrosis Development in Chronic Hepatitis C Virus Infection. <i>Clinical Science</i> , <b>2002</b> , 103, 41P-41P		
19	Intra-familial transmission of hepatitis B virus in Italy: phylogenetic sequence analysis and amino-acid variation of the core gene. <i>Journal of Hepatology</i> , <b>2002</b> , 36, 248-53	13.4	24
18	Prevalence of HBV core promoter/precore/core mutations in Gambian chronic carriers. <i>Journal of Medical Virology</i> , <b>2001</b> , 65, 664-70	19.7	23
17	Characterization of novel HLA-DR11-restricted HCV epitopes reveals both qualitative and quantitative differences in HCV-specific CD4+ T cell responses in chronically infected and non-viremic patients. <i>European Journal of Immunology</i> , <b>2001</b> , 31, 1438-46	6.1	59
16	Genetic susceptibility in chronic viral hepatitis. <i>Antiviral Research</i> , <b>2001</b> , 52, 113-6	10.8	92
15	Transmission of hepatitis B virus infection in Gambian families revealed by phylogenetic analysis. <i>Journal of Hepatology</i> , <b>2001</b> , 35, 99-104	13.4	84
14	Epidemiology of hepatitis C virus infection in seven European Union countries: a critical analysis of the literature. HENCORE Group. (Hepatitis C European Network for Co-operative Research. <i>European Journal of Gastroenterology and Hepatology</i> , <b>2000</b> , 12, 667-78	2.2	65
13	Genetic Susceptibility in Infectious Diseases. <i>Biotechnology and Genetic Engineering Reviews</i> , <b>2000</b> , 17, 255-266	4.1	5
12	Influence of MHC class II genotype on outcome of infection with hepatitis C virus. The HENCORE group. Hepatitis C European Network for Cooperative Research. <i>Lancet, The</i> , <b>1999</b> , 354, 2119-24	40	250
11	Host factors in chronic viral hepatitis. <i>Seminars in Liver Disease</i> , <b>1997</b> , 17, 345-50	7.3	15
10	Hepatitis B virus core protein mutations are concentrated in B cell epitopes in progressive disease and in T helper cell epitopes during clinical remission. <i>Journal of Infectious Diseases</i> , <b>1997</b> , 175, 1093-1007		59
9	Heterozygote advantage for HLA class-II type in hepatitis B virus infection. <i>Nature Genetics</i> , <b>1997</b> , 17, 11-2	36.3	254
8	Association of hepatitis B surface antigen carriage with severe malaria in Gambian children. <i>Nature Medicine</i> , <b>1995</b> , 1, 374-5	50.5	47
7	Association between an MHC class II allele and clearance of hepatitis B virus in the Gambia. <i>New England Journal of Medicine</i> , <b>1995</b> , 332, 1065-9	59.2	378
6	Detection of rare allelic variants of the interferon-alpha 2 gene in human genomic DNA. <i>Journal of Interferon and Cytokine Research</i> , <b>1995</b> , 15, 403-6	3.5	10

- 5 Hepatitis B virus precore/core variation and interferon therapy. *Hepatology*, **1995**, 22, 1355-1362 11.2 38
- 4 Fulminant hepatitis associated with hepatitis B virus e antigen-negative infection: Importance of host factors. *Hepatology*, **1995**, 22, 1628-1634 11.2 58
- 3 Hepatitis B Virus Infection and Immunity 283-299
- 2 Pathogenesis of Chronic Hepatitis B 308-322 1
- 1 Genomic Investigations in Viral Hepatitis: Likely to Help or Hinder? 13-18